Sugi Predict

Sugi Predict / Compounds / SCHEMBL3093501

SCHEMBL3093501

SCHEMBL3093501

CCCC[Sn](CCCC)(CCCC)c1cc2cccnc2n1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ PTGDR2 Q9Y5Y4 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.38
▸ HTT P42858 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ NOD2 Q9HC29 2/20 0.38
▸ NOD1 Q9Y239 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ENPP3 O14638 1/20 0.38
▸ CXCL8 P10145 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ LMNA P02545 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ AGTR1 P30556 2/20 0.37
▸ MITF O75030 1/20 0.37
▸ S1PR4 O95977 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2988406 0.83 LMNA (0.36) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL2982552 0.81 PTGDR2 (0.40) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL29772861 0.81 PTGDR2 (0.40) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL2994721 0.79 PTGDR2 (0.39) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL1713506 0.78 L3MBTL1 (0.62) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL26969526 0.76 L3MBTL1 (0.59) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL28253787 0.75 L3MBTL1 (0.58) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL1749134 0.75 L3MBTL1 (0.58) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL13575362 0.75 L3MBTL1 (0.58) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2
SCHEMBL16525796 0.75 L3MBTL1 (0.58) L3MBTL1PTGDR2ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 — — US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 — — US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 L3MBTL1 4205/4885PTGDR2 1281/4885ALDH1A1 3344/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 L3MBTL1 4205/4885PTGDR2 1281/4885ALDH1A1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.